Cybin Inc. (OTCMKTS:CYBN – Get Free Report) shares were down 4.3% during mid-day trading on Wednesday . The stock traded as low as $10.20 and last traded at $10.25. Approximately 204,600 shares traded hands during trading, an increase of 10% from the average daily volume of 186,805 shares. The stock had previously closed at $10.71.
Cybin Trading Down 4.3 %
The stock has a market cap of $204.92 million, a price-to-earnings ratio of -1.54 and a beta of 0.38. The firm has a fifty day simple moving average of $10.19 and a 200 day simple moving average of $3.74.
About Cybin
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Further Reading
- Five stocks we like better than Cybin
- ETF Screener: Uses and Step-by-Step Guide
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Comparing and Trading High PE Ratio Stocks
- 3 Penny Stocks Ready to Break Out in 2025
- Why Invest in High-Yield Dividend Stocks?
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
